COVID-19 and sulfonylureas: A reminder of the pleiotropic actions of an old class of drugs just before their swansong.

Koufakis, Theocharis; Popovic, Djordje S; Metallidis, Symeon; Kotsa, Kalliopi

Koufakis, Theocharis; Popovic, Djordje S; Metallidis, Symeon; Kotsa, Kalliopi.

Koufakis T; Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece.
Popovic DS; Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Centre of Vojvodina, Novi Sad, Serbia; Medical Faculty, University of Novi Sad, Novi Sad, Serbia.
Metallidis S; Infectious Diseases Division, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece.
Kotsa K; Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece. Electronic address: kalmanthou@yahoo.gr.

Metabolism ; 133: 155221, 2022 08.

Article in English | MEDLINE | ID: covidwho-1867489

Subject(s)

COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents/pharmacology; Hypoglycemic Agents/therapeutic use; Sulfonylurea Compounds/pharmacology; Sulfonylurea Compounds/therapeutic use

Keywords

COVID-19; Inflammation; Sulfonylureas

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Metabolism Year: 2022 Document Type: Article Affiliation country: J.metabol.2022.155221

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google